
Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.
Professor Matthias Augustin details the various clinical manifestations of prurigo nodularis, illustrating how different lesion types can present concurrently in patients.
Experts from different specialties use a case-based discussion to understand type 2 inflammatory diseases from a nurse practitioner perspective.

Dr. Chovatiya discusses PN, emphasizing that while itch is a major symptom, the disease's burden is multi-dimensional, affecting appearance, sleep, social life, and mental health, requiring comprehensive therapeutic solutions.

Dr. Paller explores the multifaceted impact of AD, highlighting its association with various comorbidities such as food allergies, asthma, allergic rhinitis, and mental health disorders.

Drs. Bob Geng and Lawrence Eichenfield highlight a multidisciplinary team approach to patient-centered care in diseases with type 2 inflammation

Explore the role of interleukin (IL)-33 in chronic obstructive pulmonary disease (COPD) pathophysiology and its potential as a therapeutic target.
Unpack the keys to successful disease control in CRSwNP alongside expert Prof. Vibeke Backer. Learn how to navigate treatment pathways for improved patient quality of life.

Join experts Henrik Watz, Mona Bafadhel, and Alberto Papi for an educational symposium on the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden, exploring the role of type 2 cytokines, and current and emerging therapies.

In this clip from the April WCPD 2025 symposium, Dr Paula Luna discusses how moderate-to-severe AD may hinder growth in pediatric patients.
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses the significant risk of developing other atopic diseases among infants with early-onset atopic dermatitis.